β- and γ-diketones and γ-hydroxyketones as Wnt/β-catenin signaling pathway activators

Patent metadata

Field	Value
Publication number	US-9303010-B2
Application number	US-201414547858-A
Country	US
Kind code	B2
Filing date	Nov 19, 2014
Priority date	Aug 18, 2010
Publication date	Apr 5, 2016
Grant date	Apr 5, 2016

Abstract

The present application discloses a compound which is

which activates Wnt/β-catenin signaling and thus treats or prevents diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

First claim

What is claimed is:

1. A compound which is

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound which is

and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of: a polyethylene glycol, a partial glyceride mixture of saturated vegetable fatty acids, a triglyceride, a glycol, a glycerol, and mixtures thereof.

4. The pharmaceutical composition of claim 2 , wherein the composition is a solid composition.

5. The pharmaceutical composition of claim 2 , wherein the composition is a liquid composition.

6. The pharmaceutical composition of claim 2 , wherein the composition is an emulsion.

7. The pharmaceutical composition of claim 2 , wherein the composition is a drug-eluting polymer.

8. The pharmaceutical composition of claim 2 , wherein the composition is a drug-eluting sponge.

9. The pharmaceutical composition of claim 2 , wherein the composition is formulated for oral administration.

10. A topical composition comprising a compound which is

and a pharmaceutically acceptable excipient.

11. The pharmaceutical composition of claim 9 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of: a polyethylene glycol, a partial glyceride mixture of saturated vegetable fatty acids, a triglyceride, a glycol, a glycerol, and mixtures thereof.

Assignees

• Samumed Llc

Inventors

• Kumar Kc Sunil
• Wallace David Mark
• Hood John
• Barroga Charlene F

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P7/06

  Antianaemics · CPC title